Concepts (180)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 55 | 2025 | 5097 | 5.280 |
Why?
|
| Cost-Benefit Analysis | 25 | 2023 | 253 | 3.500 |
Why?
|
| Anti-HIV Agents | 19 | 2023 | 1324 | 3.200 |
Why?
|
| Hypertension | 4 | 2024 | 419 | 2.330 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2023 | 139 | 2.030 |
Why?
|
| Humans | 67 | 2025 | 14537 | 1.950 |
Why?
|
| Epidemics | 5 | 2024 | 65 | 1.950 |
Why?
|
| South Africa | 50 | 2025 | 7596 | 1.870 |
Why?
|
| Pre-Exposure Prophylaxis | 7 | 2023 | 196 | 1.750 |
Why?
|
| Mass Screening | 13 | 2025 | 245 | 1.680 |
Why?
|
| Diabetes Mellitus | 2 | 2024 | 146 | 1.450 |
Why?
|
| Health Care Costs | 7 | 2022 | 115 | 1.430 |
Why?
|
| National Health Programs | 2 | 2019 | 78 | 1.090 |
Why?
|
| Antiretroviral Therapy, Highly Active | 6 | 2019 | 472 | 1.070 |
Why?
|
| Male | 29 | 2025 | 6754 | 1.040 |
Why?
|
| Sex Workers | 5 | 2022 | 116 | 1.030 |
Why?
|
| Immunization Programs | 2 | 2024 | 81 | 1.000 |
Why?
|
| Female | 30 | 2025 | 9103 | 0.960 |
Why?
|
| Sexual and Gender Minorities | 2 | 2022 | 29 | 0.900 |
Why?
|
| Models, Theoretical | 9 | 2024 | 80 | 0.900 |
Why?
|
| Delivery of Health Care | 5 | 2024 | 239 | 0.820 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2023 | 3 | 0.790 |
Why?
|
| Adult | 23 | 2025 | 5913 | 0.760 |
Why?
|
| Primary Health Care | 3 | 2024 | 240 | 0.750 |
Why?
|
| Noncommunicable Diseases | 1 | 2023 | 77 | 0.730 |
Why?
|
| Anti-Retroviral Agents | 4 | 2023 | 551 | 0.730 |
Why?
|
| Models, Economic | 4 | 2019 | 15 | 0.730 |
Why?
|
| Reproductive Health | 1 | 2021 | 51 | 0.680 |
Why?
|
| Adolescent | 11 | 2025 | 2985 | 0.610 |
Why?
|
| Medically Uninsured | 1 | 2019 | 9 | 0.610 |
Why?
|
| Cardiovascular Diseases | 1 | 2022 | 237 | 0.610 |
Why?
|
| Models, Biological | 1 | 2019 | 77 | 0.590 |
Why?
|
| Sexual Partners | 1 | 2020 | 215 | 0.580 |
Why?
|
| Hospitalization | 3 | 2024 | 418 | 0.570 |
Why?
|
| Communicable Disease Control | 2 | 2022 | 101 | 0.560 |
Why?
|
| Topography, Medical | 1 | 2018 | 2 | 0.560 |
Why?
|
| Disease Management | 1 | 2018 | 74 | 0.530 |
Why?
|
| Financing, Personal | 1 | 2017 | 12 | 0.530 |
Why?
|
| Program Development | 1 | 2017 | 32 | 0.500 |
Why?
|
| Young Adult | 11 | 2025 | 2498 | 0.500 |
Why?
|
| Prevalence | 7 | 2023 | 1192 | 0.490 |
Why?
|
| Drug Costs | 3 | 2023 | 18 | 0.480 |
Why?
|
| Health Promotion | 1 | 2017 | 109 | 0.460 |
Why?
|
| Occupational Health Services | 1 | 2015 | 2 | 0.460 |
Why?
|
| Poverty | 3 | 2023 | 152 | 0.460 |
Why?
|
| Pregnancy | 8 | 2024 | 1862 | 0.460 |
Why?
|
| Mining | 1 | 2015 | 41 | 0.450 |
Why?
|
| Herpes Genitalis | 2 | 2014 | 43 | 0.430 |
Why?
|
| Emtricitabine | 3 | 2022 | 78 | 0.400 |
Why?
|
| Treatment Outcome | 8 | 2023 | 889 | 0.380 |
Why?
|
| Point-of-Care Systems | 2 | 2023 | 91 | 0.380 |
Why?
|
| Tuberculosis, Pulmonary | 2 | 2012 | 324 | 0.370 |
Why?
|
| Herpesvirus 2, Human | 2 | 2014 | 43 | 0.360 |
Why?
|
| Pyridones | 2 | 2023 | 100 | 0.360 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2024 | 187 | 0.360 |
Why?
|
| Circumcision, Male | 4 | 2022 | 99 | 0.350 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2012 | 59 | 0.350 |
Why?
|
| Prospective Studies | 3 | 2024 | 1160 | 0.350 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2012 | 135 | 0.340 |
Why?
|
| Acyclovir | 1 | 2011 | 11 | 0.340 |
Why?
|
| Homosexuality, Male | 2 | 2022 | 52 | 0.340 |
Why?
|
| Public Sector | 3 | 2021 | 82 | 0.340 |
Why?
|
| Rifampin | 1 | 2012 | 197 | 0.330 |
Why?
|
| Antiviral Agents | 1 | 2011 | 111 | 0.320 |
Why?
|
| Retrospective Studies | 4 | 2024 | 799 | 0.320 |
Why?
|
| Middle Aged | 7 | 2025 | 3601 | 0.320 |
Why?
|
| CD4 Lymphocyte Count | 6 | 2017 | 656 | 0.320 |
Why?
|
| Private Sector | 2 | 2021 | 45 | 0.320 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2013 | 329 | 0.300 |
Why?
|
| Costs and Cost Analysis | 4 | 2020 | 42 | 0.300 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2009 | 33 | 0.300 |
Why?
|
| Incidence | 5 | 2023 | 685 | 0.290 |
Why?
|
| Adenine | 2 | 2022 | 91 | 0.280 |
Why?
|
| Patient Care | 2 | 2019 | 10 | 0.250 |
Why?
|
| Quality of Health Care | 2 | 2019 | 62 | 0.240 |
Why?
|
| Child | 5 | 2023 | 2242 | 0.230 |
Why?
|
| Europe, Eastern | 1 | 2024 | 3 | 0.220 |
Why?
|
| Asia, Central | 1 | 2024 | 2 | 0.220 |
Why?
|
| Transgender Persons | 1 | 2024 | 24 | 0.210 |
Why?
|
| Pandemics | 2 | 2023 | 296 | 0.210 |
Why?
|
| Health Expenditures | 1 | 2024 | 39 | 0.210 |
Why?
|
| Diketopiperazines | 1 | 2023 | 6 | 0.200 |
Why?
|
| Emigrants and Immigrants | 2 | 2017 | 11 | 0.200 |
Why?
|
| Chlamydia Infections | 1 | 2023 | 17 | 0.200 |
Why?
|
| Gonorrhea | 1 | 2023 | 20 | 0.200 |
Why?
|
| Markov Chains | 2 | 2015 | 22 | 0.200 |
Why?
|
| Tenofovir | 2 | 2022 | 171 | 0.200 |
Why?
|
| Blood Glucose | 1 | 2023 | 107 | 0.200 |
Why?
|
| Health Services Accessibility | 2 | 2019 | 280 | 0.190 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2023 | 33 | 0.190 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2023 | 103 | 0.190 |
Why?
|
| Africa South of the Sahara | 2 | 2021 | 353 | 0.190 |
Why?
|
| Algorithms | 2 | 2013 | 106 | 0.190 |
Why?
|
| Vaccination | 1 | 2024 | 365 | 0.180 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 3 | 2013 | 226 | 0.180 |
Why?
|
| Risk Factors | 2 | 2023 | 1475 | 0.170 |
Why?
|
| Adenosine Monophosphate | 1 | 2021 | 5 | 0.170 |
Why?
|
| Piperazines | 1 | 2021 | 82 | 0.170 |
Why?
|
| Vulnerable Populations | 1 | 2021 | 30 | 0.170 |
Why?
|
| Oxazines | 1 | 2021 | 81 | 0.170 |
Why?
|
| Alanine | 1 | 2021 | 31 | 0.170 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 112 | 0.170 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2021 | 85 | 0.170 |
Why?
|
| Health Services Needs and Demand | 1 | 2021 | 57 | 0.170 |
Why?
|
| Blood Pressure | 1 | 2023 | 317 | 0.170 |
Why?
|
| Unsafe Sex | 1 | 2021 | 46 | 0.170 |
Why?
|
| Urban Population | 2 | 2013 | 257 | 0.160 |
Why?
|
| Intensive Care Units | 1 | 2021 | 66 | 0.160 |
Why?
|
| Community Health Services | 1 | 2020 | 58 | 0.160 |
Why?
|
| General Practitioners | 1 | 2019 | 7 | 0.150 |
Why?
|
| Income | 1 | 2019 | 85 | 0.150 |
Why?
|
| Patient Education as Topic | 1 | 2019 | 48 | 0.140 |
Why?
|
| Budgets | 1 | 2017 | 12 | 0.130 |
Why?
|
| Malawi | 3 | 2022 | 87 | 0.130 |
Why?
|
| HIV Seropositivity | 2 | 2017 | 265 | 0.130 |
Why?
|
| Contraception | 1 | 2018 | 90 | 0.130 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2018 | 115 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 127 | 0.130 |
Why?
|
| Lost to Follow-Up | 1 | 2017 | 62 | 0.120 |
Why?
|
| Risk Assessment | 1 | 2017 | 225 | 0.120 |
Why?
|
| Public Health | 1 | 2017 | 124 | 0.120 |
Why?
|
| Absenteeism | 1 | 2015 | 10 | 0.110 |
Why?
|
| Infant | 3 | 2023 | 2244 | 0.110 |
Why?
|
| Survival Rate | 1 | 2015 | 96 | 0.110 |
Why?
|
| Cohort Studies | 2 | 2017 | 967 | 0.100 |
Why?
|
| Viral Load | 2 | 2019 | 819 | 0.100 |
Why?
|
| Organophosphonates | 1 | 2014 | 45 | 0.100 |
Why?
|
| Suburban Health Services | 1 | 2012 | 2 | 0.100 |
Why?
|
| Urban Health Services | 1 | 2012 | 10 | 0.090 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2016 | 472 | 0.090 |
Why?
|
| Length of Stay | 1 | 2012 | 43 | 0.090 |
Why?
|
| Diagnostic Equipment | 1 | 2012 | 3 | 0.090 |
Why?
|
| Mobile Health Units | 1 | 2012 | 7 | 0.090 |
Why?
|
| Zambia | 3 | 2021 | 115 | 0.090 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2016 | 529 | 0.090 |
Why?
|
| Child, Preschool | 2 | 2013 | 1748 | 0.090 |
Why?
|
| Sputum | 1 | 2012 | 135 | 0.090 |
Why?
|
| Time Factors | 1 | 2012 | 507 | 0.080 |
Why?
|
| Disease Progression | 1 | 2011 | 154 | 0.080 |
Why?
|
| Africa, Southern | 2 | 2021 | 91 | 0.080 |
Why?
|
| Burundi | 1 | 2009 | 3 | 0.080 |
Why?
|
| Forecasting | 2 | 2023 | 20 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 106 | 0.080 |
Why?
|
| Ambulatory Care | 1 | 2009 | 54 | 0.070 |
Why?
|
| Rural Population | 1 | 2013 | 654 | 0.070 |
Why?
|
| Feasibility Studies | 2 | 2023 | 101 | 0.070 |
Why?
|
| HIV-1 | 2 | 2019 | 1260 | 0.070 |
Why?
|
| Tuberculosis | 1 | 2012 | 543 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2025 | 1422 | 0.060 |
Why?
|
| Workplace | 1 | 2024 | 7 | 0.050 |
Why?
|
| Chlamydia trachomatis | 1 | 2023 | 13 | 0.050 |
Why?
|
| Neisseria gonorrhoeae | 1 | 2023 | 15 | 0.050 |
Why?
|
| Standard of Care | 1 | 2023 | 30 | 0.050 |
Why?
|
| Integrases | 1 | 2023 | 2 | 0.050 |
Why?
|
| Point-of-Care Testing | 1 | 2023 | 71 | 0.050 |
Why?
|
| Breast Feeding | 1 | 2023 | 120 | 0.050 |
Why?
|
| Prenatal Care | 1 | 2023 | 147 | 0.040 |
Why?
|
| Drug Resistance | 1 | 2021 | 35 | 0.040 |
Why?
|
| Health Facilities | 1 | 2021 | 40 | 0.040 |
Why?
|
| Zimbabwe | 1 | 2021 | 120 | 0.040 |
Why?
|
| Lesotho | 1 | 2020 | 6 | 0.040 |
Why?
|
| Community-Based Participatory Research | 1 | 2020 | 24 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2021 | 256 | 0.040 |
Why?
|
| Patient Selection | 1 | 2017 | 40 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2017 | 133 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 163 | 0.030 |
Why?
|
| Mortality | 1 | 2017 | 104 | 0.030 |
Why?
|
| Vietnam | 1 | 2013 | 13 | 0.030 |
Why?
|
| Eligibility Determination | 1 | 2013 | 16 | 0.030 |
Why?
|
| India | 1 | 2013 | 62 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2013 | 34 | 0.030 |
Why?
|
| Medical Laboratory Science | 1 | 2013 | 4 | 0.020 |
Why?
|
| Outpatients | 1 | 2013 | 38 | 0.020 |
Why?
|
| Geography | 1 | 2012 | 60 | 0.020 |
Why?
|
| Demography | 1 | 2012 | 105 | 0.020 |
Why?
|
| Contact Tracing | 1 | 2012 | 48 | 0.020 |
Why?
|
| Cost of Illness | 1 | 2013 | 167 | 0.020 |
Why?
|
| Medical Audit | 1 | 2009 | 26 | 0.020 |
Why?
|
| Ambulatory Care Facilities | 1 | 2009 | 125 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2013 | 1479 | 0.020 |
Why?
|